Items where Author is "Xu, Ziyue"

Item Type No Grouping

Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data:a retrospective analysis. (2024) Naci, Huseyin; Zhang, Yichen; Woloshin, Steven; Guan, Xiaodong; Xu, Ziyue; Wagner, Anita K. picture_as_pdf

Overall survival benefits of cancer drugs approved in China from 2005 to 2020. (2022) Zhang, Yichen; Naci, Huseyin; Wagner, Anita K.; Xu, Ziyue; Yang, Yu; Zhu, Jun; Ji, Jiafu; Shi, Luwen; Guan, Xiaodong picture_as_pdf

Cancer drug indication approvals in China and the United States:a comparison of approval times and clinical benefit, 2001–2020. Wei, Yuxuan; Zhang, Yichen; Xu, Ziyue; Wang, Guoan; Zhou, Yue; Li, Huangqianyu; Shi, Luwen; Naci, Huseyin; Wagner, Anita K.; Guan, Xiaodong picture_as_pdf

Communication of survival data in US Food and Drug Administration-approved labeling of cancer drugs. Naci, Huseyin; Guan, Xiaodong; Woloshin, Steven; Xu, Ziyue; Wagner, Anita K. picture_as_pdf

Real-world use of and spending on new oral targeted cancer Drugs in the US, 2011-2018. Fu, Mengyuan; Naci, Huseyin; Booth, Christopher M.; Gyawali, Bishal; Cosgrove, Austin; Toh, Sengwee; Xu, Ziyue; Guan, Xiaodong; Ross-Degnan, Dennis; Wagner, Anita K.